MORC6 plays a crucial role in RNA-directed DNA methylation (RdDM) as a component of the RdDM machinery, essential for gene silencing. In collaboration with SUVH2 and SUVH9, it regulates the silencing of certain transposable elements (TEs). MORC6 exhibits ATPase activity and may contribute to the regulation of chromatin architecture and condensation to maintain gene silencing. It binds DNA/RNA non-specifically and possesses endonuclease activity, potentially participating in DNA repair. Furthermore, MORC6 acts as a positive regulator in defense against the oomycete Hyaloperonospora arabidopsidis (Hpa).
Perform Western blot using Arabidopsis thaliana wild-type and morc6 knockout mutants. Validate absence of signal in mutants .
Use immunofluorescence with nuclear markers (e.g., histone H3) to confirm subcellular localization in root tip cells .
Conduct peptide competition assays by pre-incubating the antibody with the immunogen peptide; signal reduction confirms specificity .
Genetic crosses: Combine morc6 mutants with mom1 or pol V mutants to isolate RdDM-dependent effects .
ChIP-seq: Compare MORC6 binding sites in wild-type and RdDM mutants (e.g., nrpe1) to identify RdDM-independent targets .
ATAC-seq: Assess chromatin accessibility changes in morc6 mutants to distinguish chromatin compaction roles .
MORC6 interacts with PIAL2 in the MOM1 complex for RdDM-dependent silencing .
RdDM-independent functions involve chromatin compaction at stress-responsive loci .
Epistasis analysis: Compare DNA methylation levels in morc6, mom1, and double mutants using whole-genome bisulfite sequencing .
Time-course experiments: Track de novo methylation at RdDM targets (e.g., FWA) after ZF-MORC6 tethering in mutant backgrounds .
MORC6 acts downstream of MOM1 but upstream of Pol V in RdDM .
Partial redundancy with other MORC proteins explains locus-specific methylation defects .
Yeast Two-Hybrid (Y2H): Test MORC6’s GHKL domain against PIAL2 or ACD proteins .
Co-IP/MS: Immunoprecipitate MORC6-FLAG from transgenic plants and identify co-purifying partners (e.g., MBD–ACD complex) .
In vitro ATPase assays: Measure ATP hydrolysis activity of recombinant MORC6 to confirm enzymatic function .
CRISPR knockouts: Generate MORC6-deficient cell lines to assess transcriptional dysregulation (e.g., rDNA silencing) .
ChIP-qPCR: Profile MORC6 binding at disease loci (e.g., VAR1 in cancer) under stress conditions .
Transcriptome analysis: Compare RNA-seq data from patient samples with MORC6 mutations vs. wild-type .
MORC6 depletion disrupts 45S rDNA silencing via MBD–ACD recruitment .
MORC6 mutations correlate with autoimmune disorders (e.g., dermatomyositis) .
Negative controls: Use IgG from pre-immune serum and morc6 mutant lysates .
Competition controls: Include immunogen peptide in parallel IPs .
Crosslinking optimization: Test formaldehyde vs. DSG crosslinkers for chromatin-bound complexes .
MORC6 loss increases DNA accessibility for stress-responsive TFs .
Stochastic silencing in morc6 mutants suggests backup silencing mechanisms .
Multiplexed IF-FISH: Combine immunofluorescence with FISH to correlate MORC6 localization with target loci (e.g., FWA) .
Crispr-mediated epitope tagging: Endogenously tag MORC6 for native ChIP-seq .
Structure-function analysis: Express MORC6 truncations (e.g., ΔGHKL) to dissect domain roles .